pharma · Breast Cancer · NSCLC, synchronous oligo-metastatic
Impact Therapeutics
Partner Therapeutics Limited
Impact Therapeutics clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1004, 10th Floor, Lodha Supremus Saki Vihar Road, Powai, Mumbai-400072, Maharashtra 400072, IN, Lexington
- Founded
- 2010
- Employees
- 8
- Programs
- 12
- Drugs
- 26
- Patents
- 0
Impact Therapeutics projects
5 ClinicalTrials.gov programs sponsored by Impact Therapeutics.
Impact Therapeutics has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ETOP25-23 ADOPT-lung
Partner Therapeutics Limited
Stage IIB-IIIB (N2) resectable non small cell lung cancer
1 trial -
IBCSG 59-19
Partner Therapeutics Limited
Female or male patients with histologically confirmed HR-positive, HER2-negative resected isolated locoregional recurrence (ILRR) of breast cancer.
1 trial -
LIBTAYO 350 mg concentrate for solution for infusion.
Partner Therapeutics Limited
Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%
1 trial -
cyclophosphamide
Partner Therapeutics Limited
Breast Cancer
1 trial -
exemestane
Partner Therapeutics Limited
Breast Cancer
1 trial
Frequently asked questions
How many clinical projects does Impact Therapeutics have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.